On August 1, 2023 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, reported an agreement to adopt BioVolume’s leading 3D imaging and thermal technology as their primary means of capturing efficacy results (Press release, Champions Oncology, AUG 1, 2023, View Source [SID1234633581]). Through this multi-year agreement Champions Oncology will incorporate BioVolume’s cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions’ consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable the achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BioVolume is advancing global preclinical oncology by providing greater study accuracy and helping strengthen drug filings for clinical trials with a digital record of preclinical efficacy. Specifically, BioVolume detects, segments, and measures subcutaneous tumor growth in rodents. By providing traceable imaging for each volume measurement alongside the additional capture of tumor height, ensures greater reproducibility of study data and offers a statistically significant reduction in variability compared to calipers which rely on manual measurement. In silico modeling of BioVolume data demonstrates that reducing variability can decrease the chance of missing a therapeutic effect by a factor of seven in comparison to existing caliper-based processes.
Maria Mancini, Chief Operating Officer at Champions Oncology said, "We are excited to announce our partnership with BioVolume. Adopting innovative technologies to digitize preclinical lab processes is critical to generating new breakthroughs in cancer research. The partnership will enable us to provide full transparency in study data collection and analysis, more accurate and consistent data, and greater scientific confidence to the pharma and biotech research community."
"Champions Oncology and BioVolume are both forward-looking companies committed to advancing science, and we look forward to working together to enable faster, smarter, and more confident decisions to be made in the identification and development of new cancer therapeutics," said Karl Turley, BioVolume Chief Operating Officer. "Cancer research is affected by a reproducibility crisis, and we believe our unique imaging platform will help tackle this challenge by transforming reproducibility in preclinical efficacy assessments."